Shield Therapeutics plc a commercial stage specialty pharmaceutical company that focuses on commercialization of pharmaceuticals to treat unmet medical needs.
Business Segments
The company operates through Research and Development, Manufacturing and Supply Chain, and Commercial Operations segments.
Research and Development
This segment adheres to strict regulatory standards, ensuring that all products undergo rigorous testing and validation before market introduction. The R&D team collaborat...
Shield Therapeutics plc a commercial stage specialty pharmaceutical company that focuses on commercialization of pharmaceuticals to treat unmet medical needs.
Business Segments
The company operates through Research and Development, Manufacturing and Supply Chain, and Commercial Operations segments.
Research and Development
This segment adheres to strict regulatory standards, ensuring that all products undergo rigorous testing and validation before market introduction. The R&D team collaborates with various academic and industry partners to utilize cutting-edge techniques and gain insights into treatment efficacy.
Manufacturing and Supply Chain
This segment partners with third-party manufacturing services to ensure high-quality and compliant production of its pharmaceutical products. Recognizing the complexities of pharmaceutical manufacturing, the company establishes robust contracts and quality assurance mechanisms to safeguard the production processes.
Commercial Operations
This segment includes marketing, sales, and distribution strategies tailored to position Accrufer® effectively in the market. This segment employs a multifaceted approach to outreach, ensuring that health professionals are informed about the product’s benefits and efficacy. Sales teams trained in specialized pharmaceutical practices focus on establishing relationships with healthcare providers and institutions.
Business Strategy
The business strategy of the company revolves around several key pillars designed to drive growth and maximize the clinical potential of its lead therapeutic product, Accrufer®. The company prioritizes innovation and has laid out a clear roadmap that encompasses development, commercialization, and sustainability.
A foundational aspect of the company's strategy is the commitment to scientific excellence, dedicating resources to research initiatives that expand the understanding of iron deficiency and enhance treatment options. The company seeks to deepen its scientific insights by collaborating with global research institutions, ensuring that it remains at the forefront of developments in this critical area of healthcare.
Products and Services
The primary product offered by the company is Accrufer® (Feraccru®), a groundbreaking treatment for iron deficiency anemia. The company stands out as a unique pharmaceutical formulation that provides an oral iron therapy alternative for patients, addressing the limitations often encountered with traditional iron supplements and infusions.
Accrufer® is designed to deliver effective iron supplementation while minimizing the gastrointestinal side effects commonly associated with oral iron therapies. This innovation is particularly beneficial for patients with chronic conditions, including those with inflammatory bowel disease, where traditional iron intake methods for ineffective or poorly tolerated.
In addition to its flagship product, the company is committed to ongoing research and development aimed at expanding its therapeutic offerings. By exploring new formulations and delivery mechanisms, the company seeks to create a comprehensive product line addressing the diverse needs of patients facing iron deficiency.
The company emphasizes collaboration with healthcare providers to ensure effective dissemination and use of Accrufer®. This engagement is crucial for understanding patient experiences and capturing real-world evidence that can inform continuous improvement and adaptation of treatment algorithms.
Geographical Markets
The company operates in several key geographical markets, primarily focusing on regions with a high prevalence of iron deficiency and chronic conditions associated with anemia. The company has established a presence in the United Kingdom and is expanding its reach to other European markets to increase accessibility to its lead product, Accrufer®.
The entry into new geographical markets is driven by extensive market research and identification of regions where treatment options for iron deficiency are limited. The company seeks to form partnerships and collaborations with local healthcare providers and distributors in these markets to facilitate the effective introduction of its products.
Customers
The company primarily serves healthcare providers and institutions engaged in treating iron deficiency conditions. Customers include general practitioners, specialists in hematology, gastroenterology, and other healthcare pathways focusing on chronic disease management. The company intends to engage with various healthcare facilities and clinics that are integral to the treatment of patients with iron deficiency anemia.
Trade Names
The company has secured multiple patents related to Accrufer® (Feraccru®), providing legal protection against competition through intellectual property rights.
Sales and Marketing
The company employs a multi-channel sales and marketing strategy designed to effectively promote Accrufer® and engage with healthcare providers. This strategy encompasses educational initiatives, direct outreach, and collaboration efforts for increasing awareness of iron deficiency and treatment options.
A significant aspect of the marketing strategy includes engaging on-the-ground representatives who possess in-depth understanding and expertise in pharmaceutical sales. They play a crucial role in establishing connections with healthcare professionals to facilitate discussions about the product's benefits and clinical implications.
History
Shield Therapeutics plc was founded in 2008. The company was incorporated in 2008.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
